Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alibaba Group (BABA) vs Novo Nordisk A/S (NVO) Price & Performance

Alibaba GroupTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Alibaba Group vs Novo Nordisk A/S — how do they compare? Alibaba Group trades at $124.73 (market cap $309.65B), while Novo Nordisk A/S trades at $47.05 (market cap $207.31B). The key difference: Alibaba Group is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.

BABANVO
Market Cap
$309.65B$207.31B
Volume
18,069,938
Sector
Consumer CyclicalHealth
52-Week High
$189.34$63.98
52-Week Low
$94.83$35.29
Enterprise Value
$304.43B$222.02B
Dividend Yield
0.79%3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alibaba Group

Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.

Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.

Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alibaba Group

Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.

Read more on BABA

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO